Borez

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Borez

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablets (Oral preparation)
Pharmacological class Selective beta1-adrenergic receptor blocker
General purpose Cardiovascular system support
Origin Synthetic compound

What Type of Medicine is Borez?

Borez is a synthetic compound classified as a Selective beta1-adrenergic receptor blocker, placing it within the broader group of Beta-blockers. Borez is clinically recognized for its cardioselectivity, which means its action is highly focused on regulating cardiac activity. This prescription-only medicine contains the active substance Bisoprolol fumarate and is positioned for long-term management in the adult patient group. The compound's established efficacy in stabilizing cardiac function has made the INN, Bisoprolol, a core component in many cardiovascular regimens.

The Composition: Active Ingredient Bisoprolol Fumarate

The composition of Borez is defined by its sole active ingredient, Bisoprolol fumarate, presented as a single-ingredient product. This compound is delivered as an Oral preparation in the form of Film-coated tablets, a format distinguished by its convenience for daily ingestion and systemic delivery. The chemical structure of Bisoprolol fumarate, defined by the formula C18H31NO4 for the base, is characterized. Its therapeutic effect stems reliably and solely from this one compound. The consistent presentation in a film-coated tablet ensures accurate and steady delivery of the substance.

How Borez Relates to Cardiovascular Support

The general purpose of Borez is to provide foundational support for stable cardiovascular function by promoting more efficient cardiac performance. By affecting the heart’s response to nerve signals, the medication lessens the heart's overall workload and demand for oxygen. The overall benefit for the patient is the systematic stabilization of the circulatory system, aiding in the maintenance of a steady heart rhythm and regulated blood pressure. Its general application involves supporting the heart when managing conditions that place excessive strain on the circulatory system, such as elevated blood pressure.

Regulatory References

  1. MedlinePlus: Bisoprolol Drug Information

What side effects are possible with Borez?

Possible Side Effects and Safety Information

Borez (Bisoprolol fumarate) is a medication whose safety profile is officially documented by government regulatory bodies, classifying possible effects by frequency and the physiological system affected. The data ranges from very common reactions to rare and clinically significant safety concerns.

Frequency-Classified Adverse Reactions

The following frequency classifications are used to categorize official reports of adverse reactions:

  • Very Common: Slow heart rate (Bradycardia), particularly documented in patients treated for stable chronic heart failure.
  • Common: Dizziness, Headache (often at treatment initiation), Fatigue, gastrointestinal symptoms (Nausea, Diarrhea, Constipation), and Hypotension (low blood pressure). The sensation of coldness or numbness in the extremities is also classified as common.
  • Uncommon: Sleep disorders, Depression, and Bronchospasm (especially in patients with pre-existing obstructive airway disease).
  • Rare/Very Rare: These include Hearing impairment, Hepatitis, Alopecia (hair loss), and the potential for Psoriasis to be provoked or worsened.

Safety-Related Restrictions and Considerations

The official labeling defines situations where Borez should not be used (Contraindications) due to severe risk. These include Acute Heart Failure requiring intravenous support, Cardiogenic Shock, specific forms of severe Heart Block (second- or third-degree AV block), and severe Hypotension.

Population-specific safety considerations are also documented. For instance, beta-blockers may mask typical signs of low blood sugar (hypoglycemia) in individuals with Diabetes Mellitus, and caution is advised for patients with severe Renal or Hepatic Impairment, potentially requiring a maximum dose restriction. Additionally, the risk of side effects like dizziness and headache is explicitly stated to be higher at the start of treatment and is often transient.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes a Borez overdose as a serious event defined by severe physiological disturbances. The profile is strictly based on documented manifestations found in government prescribing information.

Feature Official Regulatory Statement
Documented overdose presentations Overdose may present as Bradycardia (abnormally slow heart rate), severe Hypotension, Atrioventricular (AV) conduction disturbances, Bronchospasm, Hypoglycemia, Confusion, Coma, and Convulsions (Seizures).
Physiological systems affected (as stated in label) Cardiovascular, Respiratory, Central Nervous System (CNS), and Metabolic systems.
Population-specific overdose notes The risk of Hypoglycemia is a specific concern in the overdose management of children.

Official Emergency-Response Statements

  • Immediate Action Required: Urgent medical attention must be sought immediately if an overdose is suspected or if any severe manifestations such as shock, severe bradycardia, coma, or seizures occur.
  • Supportive Management: Treatment is symptomatic and supportive. No specific antidote is known. Management may involve the use of agents like Glucagon or Atropine to address specific effects, and continuous ECG monitoring is required.

Connection to the overall overdose profile

The official Borez overdose profile is strictly defined by the documented physiological disturbances and their potential for severe, life-threatening outcomes, including Cardiac Arrest and Cardiogenic Shock. Regulatory documents mandate the immediate seeking of medical attention upon suspicion of overdose and describe management as procedural, relying exclusively on symptomatic support and continuous observation requirements.

Therapeutic Uses of Borez

What Borez Treats: Main Uses and Benefits

Borez (which contains the active ingredient bortezomib) is a medication used in targeted therapy. Its primary therapeutic domain is applied across domains where additional symptomatic support is needed. The medication is commonly used across conditions presenting with acute episodes, specifically in the management of two conditions: multiple myeloma (MM) and mantle cell lymphoma (MCL).

The medication is generally relevant in contexts involving heightened systemic burden. Clinical scenarios often involve phases where symptoms become more noticeable. In these conditions, Borez helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load. The medication supports general well-being during symptomatic phases.

“It may assist with maintaining functional stability and coping more steadily with symptom fluctuations.”

The medication is applied in addressing symptoms related to heightened physiological activity and related discomfort.

Quick Fact: Symptomatic Support for Physiological Strain
May assist with easing symptoms that create noticeable physiological strain during periods of acute or episodic changes.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Borez — Official Regulatory Information

This section outlines the officially documented eligibility status for Borez (Bortezomib), based strictly on governmental prescribing labels.

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label): Adult patients with Multiple Myeloma or Mantle Cell Lymphoma.
Populations for whom use is contraindicated: Patients with known hypersensitivity (including anaphylaxis) to bortezomib, boron, or mannitol. Use via the intrathecal administration route is also contraindicated.
Age-related eligibility rules: Approved for adult patients. Safety and efficacy have not been established in pediatric patients (under 18). No overall restrictions exist for the elderly.
Condition-specific eligibility rules: Moderate or severe hepatic impairment requires a modified starting regimen. Severe renal impairment (including dialysis patients) is conditional on administration after the dialysis procedure.
Pregnancy and lactation eligibility status: Pregnancy use can cause fetal harm, and potential risk must be communicated. Women are advised against breastfeeding.
Eligibility-related restrictions: Reproductive potential requires the mandatory use of effective contraception for both female and male patients. Patients with pre-existing severe neuropathy require a careful risk-benefit assessment before use.

Connection to the overall eligibility profile: The regulatory documents strictly define the patient population by establishing clear absolute prohibitions (contraindications), an unestablished status for children, and imposing specific conditional eligibility requirements related to pre-existing organ function and comorbidity status. This structure ensures use is limited only to groups where regulators have confirmed an acceptable eligibility profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Borez (Bisoprolol fumarate) is defined by official regulatory documents detailing both pharmacodynamic and pharmacokinetic patterns, focusing on substances that modify cardiac activity or drug clearance.

Pharmacodynamic and Contraindicated Interactions

Co-administration with other Beta-blocking agents is contraindicated due to the risk of excessive reduction of sympathetic activity. Interactions with several cardiovascular drug classes are officially classified for use with caution, primarily due to additive effects on heart rate and blood pressure.

Interacting Product Category Officially Documented Outcome
Calcium Antagonists (Verapamil, Diltiazem) May produce excessive reduction of sympathetic activity.
Antiarrhythmic Agents (Disopyramide, Amiodarone) Increased risk of bradycardia (slow heart rate).
Digitalis Glycosides (Digoxin) Increased risk of bradycardia by slowing conduction.
Clonidine Must be discontinued several days before Clonidine withdrawal to mitigate rebound hypertension risk.

Pharmacokinetic and Substance Interactions

The official label documents that co-administration with Rifampin increases the metabolic clearance of Borez, resulting in a shortened elimination half-life. Alcohol may contribute to an additive effect in lowering blood pressure. The drug's absorption is not affected by co-administration with food. For individuals with renal impairment (creatinine clearance less than 40 mL/min), the plasma half-life is officially noted as being increased approximately threefold.

Mechanism of Action

Selective Blockade of Cardiac Stress Receptors

Borez (Bisoprolol fumarate) functions as a highly specific competitive antagonist that targets the mathbfbeta1-adrenergic receptors predominantly located in the myocardium and its electrical conduction system. By occupying these receptor sites, the drug prevents the binding of endogenous catecholamines (like epinephrine), suppressing the stimulatory effects of the sympathetic nervous system on the heart. This molecular blockade reduces the rate of signaling pathways within the heart cells, resulting in a negative chronotropic (slowing of heart rate) and negative inotropic (reduced force) effect, which ultimately results in a reduction of myocardial energy consumption and cardiac output.

Systemic Modulation via Kidney Signaling

The mechanism extends beyond the heart to the renal systems. Borez blocks beta1-receptors on the juxtaglomerular apparatus, thereby suppressing the release of renin, the rate-limiting enzyme in the Renin-Angiotensin System (RAS). This inhibition reduces the subsequent formation of powerful vasoconstrictors, contributing to the systemic reduction of arterial pressure and influencing the level of systemic vascular resistance throughout the circulatory system.

Dosage and Administration Information

How to Use Borez

The usage of Borez (bortezomib) is highly structured, defining the conditions for administration, dosage calculation, and scheduling. The medicine is delivered through injectable routes only, specifically as either an Intravenous (IV) bolus injection or a Subcutaneous (SC) injection.

Administration Standards and Dosing Regimen

The standard starting dosage is 1.3 mg/m^2, calculated individually based on the patient's Body Surface Area (BSA). Specific dose reductions (to 1.0 mg/m^2 or 0.7 mg/m^2) may be implemented based on patient tolerance during a regimen.

Administration Scope Official Requirement
Preparation Reconstituted using 0.9% Sodium Chloride solution (Final concentration varies by route).
IV Administration Must be administered as a bolus over 3 to 5 seconds.
SC Administration Requires site rotation (thigh or abdomen) and new injections must be at least one inch from the previous site.
Hepatic Adjustment A lower starting dose of 0.7 mg/m^2 is required for patients with moderate or severe liver impairment.

Treatment Frequency and Cycles

Borez is administered in cyclic regimens, such as twice weekly (e.g., Days 1, 4, 8, and 11) or once weekly patterns, which alternate with mandatory rest periods. A crucial procedural condition requires that a minimum of 72 hours must separate the administration of any two consecutive doses. The overall course of use is defined by a specified number of these treatment cycles.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Borez (Bisoprolol Fumarate)

The research evidence for Borez, which contains the active ingredient Bisoprolol fumarate, comes primarily from clinical trials focused on major long-term cardiovascular conditions. Studies include large, randomized trials that compare the medicine to an inactive substance (placebo) and long-term observational studies that monitor its use in real-world settings.

Evidence for Use in Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)

Research for this condition involves a sequence of large-scale, randomized, double-blind, placebo-controlled trials conducted on adult populations. These studies were designed to monitor major, long-term outcomes, including all-cause patient survival and the frequency of hospitalizations (outcomes related to systemic or functional imbalance). Research highlights changes measured during the study period: trials reported specific patterns observed in patient survival rates over intermediate-term follow-up (e.g., around 1 to 2 years) and described different frequencies of hospitalization between groups. However, long-term outcomes are not fully established by randomized data extending beyond the initial core trials, and the bulk of the high-level evidence involves HFrEF, providing limited insight into outcomes for heart failure with preserved ejection fraction (HFpEF).

Evidence for Use in Essential Hypertension (High Blood Pressure)

The research examined Bisoprolol fumarate in randomized controlled trials exploring changes in blood pressure (BP) and heart rate. These studies typically monitored changes in resting and ambulatory systolic and diastolic BP, which are outcomes monitoring physiological strain. Studies reported whether participants in the tested groups reached defined blood pressure targets and monitored patterns related to measured changes in blood pressure. A key research limitation is that many studies focused mainly on the surrogate endpoint of BP reduction; therefore, comparative evidence from definitive, long-term trials powered specifically to assess a reduction in major clinical events like stroke is less extensive.

Evidence in Specific Patient Groups and Gaps

The evidence for Chronic Stable Angina Pectoris comes from randomized trials that explored outcomes related to physical discomfort and episodic changes, such as the frequency of angina episodes and capacity to exercise. The core research for all indications was primarily conducted on adult patients, and extensive subgroup analyses included patients regardless of age. Studies also monitored older adults, and research reports that age was not associated with unique patterns in the study populations. However, data for certain groups remain insufficient, such as children and complex populations. Research highlights what is still uncertain: comparative evidence on long-term cardiovascular event reduction in essential hypertension is not as robust as for heart failure, and certainty remains low for predictions outside of the major adult study populations.

Frequently Asked Questions (FAQ)

Common questions about Borez (FAQ)


Q: How quickly does Borez start to work?

The onset of action depends on the condition being managed. For high blood pressure, an initial reduction in blood pressure may begin in about two hours, but the maximum blood pressure-lowering effect is typically fully established after two to six weeks of regular use. When used for chronic heart failure, the process involves careful dose adjustments over an extended period, and it may take several weeks or months for the full therapeutic pattern to be observed.


Q: Does Borez need to be taken long-term?

Official information indicates that treatment with Borez is generally intended for long-term management of chronic conditions, such as high blood pressure and chronic heart failure. This class of medication is typically designed to provide sustained support for stable cardiovascular function over time.


Q: Is it common to feel tired after starting Borez?

Official safety data lists both fatigue and asthenia (unusual weakness or lack of energy) as Common side effects of Borez. These effects are often described as mild and may be more noticeable at the very beginning of treatment, sometimes disappearing within the first couple of weeks.


Q: Can Borez cause weight gain or loss?

Official product information reports that Borez may be associated with unspecified weight changes as a less common effect during treatment. Regulatory warnings indicate that sudden, unexplained weight gain may be a sign of a serious condition like fluid retention related to heart failure, which should be monitored by a professional.


Q: What happens if I miss a dose of Borez?

Regulatory patient information advises taking a missed dose as soon as it is remembered that same day. However, if the next day has already begun, the missed dose should be skipped entirely, and the next dose should be taken at the usual time. Official instructions state that a double dose should not be taken to compensate for a missed one.


Q: How long do the effects of Borez last in the body?

The plasma elimination half-life for Borez, which is the time required for half of the drug to be cleared from the bloodstream, is approximately 10 to 12 hours for most individuals. This pharmacological characteristic supports its therapeutic efficacy being sustained over a full 24-hour period when administered once daily.


Q: Does taking Borez require regular blood work or monitoring?

Regulatory documents emphasize that taking Borez requires close monitoring by a healthcare provider, particularly during the initial phase of treatment when the dose is being established. This monitoring is focused on the patient's general physiological response and symptoms related to the condition being treated, as defined in clinical guidelines.


Q: How soon after stopping Borez are the drug's effects completely gone?

If a healthcare provider determines that treatment with Borez should be discontinued, the medicine and its primary effects are generally estimated to be completely cleared from the body within two to three days.


Q: Is it possible to take Borez with food, even if not explicitly required?

Yes, official product information confirms that the medicine can be taken either with or without food. Its absorption into the body is not clinically affected by taking it at the same time as a meal.


Q: Can Borez be taken with antacids or acid reflux medications?

Official data suggests that co-administration with certain antacids, specifically those containing calcium carbonate, may potentially decrease the effects of Borez. Official information indicates that separating the administration times of these medications by at least two hours is sometimes required to avoid a decrease in Borez's effects.


Q: Can Borez be used by people who have allergies to certain medications?

Borez is contraindicated (should not be used) if a patient has a known hypersensitivity or allergy to the active substance, bisoprolol fumarate, or any other ingredient in the product. Regulatory information also notes that beta-blockers may potentially increase a person's sensitivity toward allergens in general.


Q: What should I do if I experience a mild side effect from Borez?

Official patient information often describes basic coping strategies for common, mild effects, such as resting for dizziness or staying well-hydrated for digestive upset. Official documentation notes that patients should seek the guidance of a healthcare provider if symptoms persist, worsen, or cause concern, allowing them to determine the appropriate course of action.


Q: Can taking Borez affect mood or mental health?

Yes, official safety data lists potential effects on the central nervous system. Uncommon side effects include sleep disorders and depression, while nightmares and hallucinations are listed as Rare side effects. These effects pertain to mental health and nervous system function.


Q: Are there any major drug classes that should always be avoided with Borez?

Regulatory documents state that co-administration with other Beta-blocking agents is strictly contraindicated (must be avoided). Combinations are also generally not recommended with certain Calcium Antagonists (like verapamil or diltiazem), specific Class I Antiarrhythmic agents, and Centrally Acting Antihypertensive agents due to the risk of excessive heart rate or blood pressure reduction.


Q: What happens if a person takes too much Borez?

Taking too much Borez can lead to an excessive decrease in heart rate (bradycardia), dangerously low blood pressure (hypotension), heart failure, and difficulty breathing (bronchospasm). Official patient information states that immediate emergency medical services should be contacted in the event of a suspected overdose.


Q: Does Borez interact with birth control pills?

Official pharmacokinetic studies have not documented a clinically relevant interaction between Borez and hormonal contraceptives. Regulatory sources typically do not report a direct interaction that affects the overall effectiveness of birth control pills.


Q: Are there any specific medical tests needed before starting Borez?

While there are no universally mandated tests, regulatory information advises special caution and potential extra checks for patients with certain pre-existing conditions, such as kidney or liver problems, or severe heart conditions. The requirement for specific tests (such as an ECG or blood work) is based on the prescribing professional’s assessment of the patient’s clinical status and the official regulatory guidelines for the drug.


Q: Can Borez cause changes in sleep patterns?

Yes, official safety documents list 'sleep disorders' as an Uncommon side effect of the medicine. This category may include difficulties falling asleep or staying asleep, or other disturbances in sleep patterns.


Q: What are the official sources for information on Borez?

Authoritative and factual information on Borez is published by government bodies and regulatory agencies worldwide. These sources include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.


Q: Is the active ingredient in Borez available under other names?

Yes, the active ingredient in Borez, which is bisoprolol fumarate, is a well-established compound. It is sold under several different brand names globally, depending on the manufacturer and country. All these brands contain the same core active substance.


Q: What is the typical timeframe for a doctor to review treatment with Borez?

For chronic heart failure, the treatment involves a strict initial dose titration phase with defined steps for dose increases, during which frequent medical review is necessary. For other uses, the need for review is based on established medical practice and patient response, which varies by individual.


Q: Do older adults need a different dose of Borez than younger adults?

For conditions like hypertension and angina, no dosage adjustment is typically required specifically for older adults. However, regulatory standards recommend that all patients should be started on the lowest possible dose and carefully monitored.


Q: What is the purpose of the different strengths Borez is available in?

Borez is available in different strengths (e.g., 1.25 mg, 2.5 mg, 5 mg, 10 mg). These different options are necessary to allow for the gradual dose titration that is required to find the appropriate and well-tolerated dose for each patient, especially when managing chronic heart failure.


Q: Does Borez affect a person's ability to drive or operate machinery?

Official information advises caution, stating that the drug may affect the ability to drive or operate machinery. This is due to potential side effects like dizziness, headache, or fatigue, which may be more pronounced at the beginning of treatment or when changing doses.


Q: What do official sources say about stopping Borez?

Regulatory documents explicitly advise that treatment should not be stopped abruptly. If discontinuation is necessary, the dosage should be reduced gradually, typically slowly lowered over at least one week, because sudden withdrawal can lead to a temporary worsening of the patient's underlying condition.


Q: Why do some people stop taking Borez?

Official labeling documents suggest that reasons that may lead to the discontinuation of Borez treatment include experiencing hypotension (low blood pressure), excessive bradycardia (slow heart rate), or a transient worsening of heart failure. These events may require the dose to be lowered or the treatment to be stopped entirely.


Q: Is the long-term safety of Borez well-established?

Borez is generally considered safe for long-term use and is often prescribed for conditions requiring sustained management. The evidence for its main uses relies on studies designed for long-term patient monitoring. However, as with any medicine, the research summaries indicate that definitive randomized data on all major long-term outcomes remains limited for some indications.

How should Borez be stored and disposed of?

Storage Conditions and Container Requirements

Unopened vials of Borez (bortezomib) must be stored at Controlled Room Temperature (20 C to 25 C). The product must be retained in its original package and actively protected from light to maintain stability. This proper storage is required to ensure the 24-month expiration period is valid. The drug is classified as a hazardous substance, which dictates specific handling and disposal protocols.

Handling and Disposal as a Hazardous Drug

Handling and preparation of the product must follow established guidelines for hazardous drugs, mandating the use of protective clothing to prevent skin contact. All unused, expired product and contaminated materials must be disposed of strictly according to local and federal cytotoxic waste regulations. Contaminated sharps must be placed into a designated hazardous sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Borez found in:

A-Z Index: